Routine care of peripheral intravenous catheters versus clinically indicated replacement: randomised controlled trial. (8th July 2008)

• Record Type: Journal Article
• Authors: Webster, Joan; Clarke, Samantha; Paterson, Dana; Hutton, Anne; Dyk, Stacey van; Gale, Catherine; Hopkins, Tracey
• Is Part Of: BMJ. Volume 337(2008)
• Publication Date: 2008-07-08
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Periodicals; 610
• DOI: 10.1136/bmj.a339
• Languages: English
• ISSNs: 0007-1447

Abstract

Abstract : Objective To compare routine replacement of intravenous peripheral catheters with replacement only when clinically indicated. Design Randomised controlled trial. Setting Tertiary hospital in Australia. Participants 755 medical and surgical patients: 379 allocated to catheter replacement only when clinically indicated and 376 allocated to routine care of catheter (control group). Main outcome measure A composite measure of catheter failure resulting from phlebitis or infiltration. Results Catheters were removed because of phlebitis or infiltration from 123 of 376 (33%) patients in the control group compared with 143 of 379 (38%) patients in the intervention group; the difference was not significant (relative risk 1.15, 95% confidence interval 0.95 to 1.40). When the analysis was based on failure per 1000 device days (number of failures divided by number of days catheterised, divided by 1000), no difference could be detected between the groups (relative risk 0.98, 0.78 to 1.24). Infusion related costs were higher in the control group (mean $A41.02; £19.71; €24.80; $38.55) than intervention group ($A36.40). The rate of phlebitis in both groups was low (4% in intervention group, 3% in control group). Conclusion Replacing peripheral intravenous catheters when clinically indicated has no effect on the incidence of failure, based on a composite measure of phlebitis or infiltration. Larger trials are needed to test this finding using phlebitis alone as a more clinically meaningful outcome. Registration number Australian New Zealand Clinical Trials Registry ACTRN12605000147684.